{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-017792","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.851485+00:00","generated_at":"2026-06-23T21:25:10.673476+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Takeda terminates collaboration; Finch regains full rights to IBD candidates FIN-524 and FIN-525","bullets":["Takeda terminated collaboration for convenience effective Nov 17, 2022; Finch regains worldwide rights to FIN-524 and FIN-525.","Finch received over $44M total from Takeda ($10M upfront, $4M milestones, over $30M R&D reimbursement).","Finch will receive royalty-free license to all data and intellectual property generated during the collaboration.","Finch is conducting a portfolio review and assessing financial and strategic impact of the termination.","No new revenue or guidance provided; future development path for IBD candidates uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-017792","json":"https://secwatch.observer/filing/0000950170-22-017792.json","markdown":"https://secwatch.observer/filing/0000950170-22-017792.md","text":"https://secwatch.observer/filing/0000950170-22-017792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022017792/0000950170-22-017792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022017792/fnch-20220819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:25:10.673476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}